Editorial & Columns Union Budget 2026-27: Impact on Pharmaceutical Sector February 5, 2026 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Pharma Companies Adapting to Jan Aushadhi Competition January 23, 2026 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25 Review: Surge in Employment and Salary in Pharma Companies September 18, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25: Mapping R&D Expenditure of Pharma Companies September 11, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25 Review: Capital Efficiency of Pharmaceutical Companies in India August 20, 2025 | Dr. Anil Kumar Angrish, Robin Kumar | No Comments | More
Editorial & Columns Market Access- Global Footprint of Indian Pharma Companies August 12, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25 Review: Operational Efficiency of Pharmaceutical Companies in India July 31, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Pharma Companies Gaining Foothold in Consumer Healthcare Space July 16, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Licensing Route: Cues from Global Pharma MNCs for Indian Pharma Companies June 26, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Revenue, EBITDA and Market Capitalisation: Linkage in Valuation of Pharma Companies in India June 11, 2025 | Dr. Anil Kumar Angrish | No Comments | More